NERLYNX DIN 02490536
Status: Marketed
Holder: KNIGHT THERAPEUTICS INC.
Molecule: NERATINIB (NERATINIB MALEATE)
Available to quote
Health Canada record
| Active ingredient(s) | NERATINIB (NERATINIB MALEATE) 40 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EH02 NERATINIB |
| Original market date | 20-Dec-2019 |
| Current status date | 20-Dec-2019 |
| Source | Health Canada DPD |
Establishment licence of the holder
Knight Therapeutics Inc. — licence 3-002350, currently licensed, last inspection rating C (2025-11-05).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 22662 | 2019-09-18 | New Drug Submission (NDS) | Administrative: Change in Product Ownership |
| 22406 | 2019-07-16 | New Drug Submission (NDS) |